Drug (ID: DG00039) and It's Reported Resistant Information
Name
Sulfasalazine
Synonyms
Sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine
    Click to Show/Hide
Indication
In total 2 Indication(s)
Irritable bowel syndrome [ICD-11: DD91]
Approved
[1]
Rheumatoid arthritis [ICD-11: FA20]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
Rheumatoid arthritis [ICD-11: FA20]
[2]
Target ATP-binding cassette transporter G2 (ABCG2) ABCG2_HUMAN [1]
Nuclear factor NF-kappa-B (NFKB) NFKB1_HUMAN ;
NFKB2_HUMAN ;
TF65_HUMAN ;
RELB_HUMAN ;
REL_HUMAN
[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C18H14N4O5S
IsoSMILES
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
InChI
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
InChIKey
NCEXYHBECQHGNR-UHFFFAOYSA-N
PubChem CID
5339
ChEBI ID
CHEBI:9334
TTD Drug ID
D02ZTJ
VARIDT ID
DR00201
INTEDE ID
DR1513
DrugBank ID
DB00795
Type(s) of Resistant Mechanism of This Drug
  IDUE: Irregularity in Drug Uptake and Drug Efflux
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-13: Digestive system diseases
Click to Show/Hide the Resistance Disease of This Class
Ulcerative colitis [ICD-11: DD71]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) [1]
Molecule Alteration Expression
Down-regulation
Sensitive Disease Ulcerative colitis [ICD-11: DD71.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model CaCo2 cells Colon Homo sapiens (Human) CVCL_0025
IPS cells Colon Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
qPCR
Experiment for
Drug Resistance
Ussing chamber system assay
Mechanism Description Digoxin and fexofenadine (each 5 uM) were selected as P-gp substrates, and sulfasalazine and rosuvastatin (each 5 uM) were selected as BCRP substrates to evaluate the efflux transport mediated by P-gp and BCRP. PSC833 (15 uM) and ko143 (15 uM) were used as typical inhibitors of P-gp and BCRP, respectively. Serosal-to-mucosal transport of all the tested P-gp and BCRP substrate drugs was significantly decreased or tended to decrease in the presence of P-gp/BCRP inhibitor cocktail.
ICD-15: Musculoskeletal/connective-tissue diseases
Click to Show/Hide the Resistance Disease of This Class
Rheumatoid arthritis [ICD-11: FA20]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) [2]
Molecule Alteration Expression
Up-regulation
Resistant Disease Rheumatoid arthritis [ICD-11: FA20.0]
Experimental Note Identified from the Human Clinical Data
Mechanism Description MTX is a substrate for eight ABC transporters. In vitro studies demonstrated that RAFLS treated with MTX had higher ABCB1 expression levels than controls, with a positive correlation between ABCB1 expression levels and RA treatment duration. In addition to MTX, other DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, azathioprine), glucocorticoids (e.g. betamethasone, dexamethasone), and NSAIDs (e.g. celecoxib and indomethacin) are also substrates of ABC transporters.
References
Ref 1 Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum. Drug Metab Dispos. 2021 Jan;49(1):84-93. doi: 10.1124/dmd.120.000138. Epub 2020 Oct 21.
Ref 2 Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors .Curr Opin Pharmacol. 2020 Oct;54:59-71. doi: 10.1016/j.coph.2020.08.002. Epub 2020 Sep 14. 10.1016/j.coph.2020.08.002

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.